Recursion director Christopher Gibson disposes of 60,000 shares for $134,800

Recursion Pharmaceuticals, Inc. Class A

Recursion Pharmaceuticals, Inc. Class A

RXRX

0.00
  • Recursion Pharmaceuticals director Christopher Gibson reported sales of 40,000 Class A common shares at USD 3.37 on May 7, 2026.
  • He also reported a gift of 20,000 Class A common shares.
  • He acquired 60,000 Class A common shares at USD 0, lifting direct holdings to 966,556 shares before reported dispositions reduced that figure to 906,556 shares.
  • Filing flagged transactions under a Rule 10b5-1 trading plan adopted May 12, 2025.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Recursion Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001856369-26-000015), on May 08, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.